The Johns Hopkins University

Niyada Hin

Barbara S Slusher

Takashi Tsukamoto

Camilo Rojas

Dana Victor Ferraris

Bridget Duvall

Ajit G Thomas

Ondrej Stepanek

Small molecule inhibitors of neutral sphingomyelinase 2 (nSMase2) and their use for treating neurodegenerative diseases, such as, neurodegenerative diseases associated with high levels of ceramide, including, but not limited to Alzheimer's disease (AD), HIV-associated neurocognitive disorder (HAND), multiple sclerosis (MS), and amyotrophic lateral sclerosis (ALS), and, in other aspects, for treating cancer or HIV-1, are provided.

Small molecule neutral sphingomyelinase 2 (nSMase2) inhibitors

D-amino acid oxidase (DAAO) inhibitors and methods of their use, either alone or in combination with D-serine or D-alanine, to facilitate allosteric activation of NMDA receptor-mediated neurotransmission and methods of their use as therapeutic agents for treating a subject afflicted with one or more cognitive-disorders, such as schizophrenia, including subjects suffering from negative symptoms and cognitive impairments, post-traumatic stress disorder (PTSD), or pain, are disclosed.

Inhibitors of D-amino acid oxidase

Growing community of inventors

Laurel, MD, United States of America

Niyada Hin